Treatment decisions based on individual estimated lifetime benefit versus individual estimated 10-year absolute risk reduction: a cost-effectiveness analyses with PCSK9 inhibition.
Decline over the years in the risk of cardiovascular events in patients with clinical manifest vascular disease is explained by change in cardiovascular risk factors and atherosclerotic burden.
Event:
ESC Congress 2016
Topic:
Epidemiology, lipids
Session:
Lipoproteins and real life: what the randomized clinical trials do not show us